Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody.
Virology
; 558: 28-37, 2021 06.
Article
in English
| MEDLINE | ID: covidwho-1057461
ABSTRACT
To help fight COVID-19, new molecular tools specifically targeting critical components of the causative agent of COVID-19, SARS-Coronavirus-2 (SARS-CoV-2), are desperately needed. The SARS-CoV-2 nucleocapsid protein is critical for viral replication, integral to viral particle assembly, and a major diagnostic marker for infection and immune protection. Currently the limited available antibody reagents targeting the nucleocapsid protein are not specific to SARS-CoV-2 nucleocapsid protein, and sequences for these antibodies are not publicly available. In this work we developed and characterized a series of new mouse monoclonal antibodies against the SARS-CoV-2 nucleocapsid protein, with a specific clone, mBG86, targeting only SARS-CoV-2 nucleocapsid protein. The monoclonal antibodies were validated in ELISA, Western blot, and immunofluorescence analyses. The variable regions from six select clones were cloned and sequenced, and preliminary epitope mapping of the sequenced clones was performed. Overall, these new antibody reagents will be of significant value in the fight against COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Coronavirus Nucleocapsid Proteins
/
SARS-CoV-2
/
COVID-19
/
Antibodies, Monoclonal
/
Antibodies, Viral
Type of study:
Observational study
/
Prognostic study
Limits:
Animals
/
Female
/
Humans
Language:
English
Journal:
Virology
Year:
2021
Document Type:
Article
Affiliation country:
J.virol.2021.01.003
Similar
MEDLINE
...
LILACS
LIS